Details of the Drug
General Information of Drug (ID: DMIZB81)
Drug Name |
Pyrazine-2-carboxylic acid adamantan-1-ylamide
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL253348; Pyrazine-2-carboxylic acid adamantan-1-ylamide; BAS 03365795; AC1MG7YQ; Cambridge id 7248781; Oprea1_265306; Oprea1_647087; MLS000088554; cid_2931812; MolPort-001-540-487; HMS2379I12; ZINC4197514; N-adamantanylpyrazin-2-ylcarboxamide; N-1-adamantyl-2-pyrazinecarboxamide; BDBM50231727; STK431969; AKOS000665660; N-(1-adamantyl)pyrazine-2-carboxamide; SDCCGMLS-0024327.P002; MCULE-4724742312; SMR000071836; ST50923663
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 257.329 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 2.1 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||
References